Eloxx Pharmaceuticals

Company snapshot

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Eloxx Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Eloxx Pharmaceuticals.

1. Jun 5, 2026 Clinical update

   Placebo — Phase 1

2. May 23, 2026 Clinical update

   ELX-02 — Phase 2

3. May 23, 2026 Clinical update

   ELX-02 — Phase 2

4. May 23, 2026 Clinical update

   ELX-02 — Phase 2

5. May 23, 2026 Clinical update

   Exaluren — Phase 2

View all clinical trial activity →

• What is Eloxx Pharmaceuticals?

  Eloxx Pharmaceuticals is a biotech organization headquartered in Watertown, USA. It trades on NYSE under ticker ELOX. Primary therapeutic focus areas include Genetic Disease, Alport Syndrome, Cystic Fibrosis, Genetic Diseases, Impaired Renal Function. NovaPharmaNews links 7 clini

• Is Eloxx Pharmaceuticals publicly traded?

  Yes. Eloxx Pharmaceuticals is listed with ticker ELOX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Eloxx Pharmaceuticals develop or market?

  We link 1 drug profile(s) where Eloxx Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/eloxx-pharmaceuticals#company-drugs.

• What are the latest developments for Eloxx Pharmaceuticals?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Eloxx Pharmaceuticals focus on?

  Eloxx Pharmaceuticals focuses on Genetic Disease, Alport Syndrome, Cystic Fibrosis based on our analysis of their pipeline programs and drug development activities.